Dexamethasone did not suppress immune boosting by personalized peptide vaccination for advanced prostate cancer patients

Prostate

Volumn 68, Issue 16, 2008, Pages 1753-1762

  Naito, Masayasu ^a   Itoh, Kyogo ^a   Komatsu, Nobukazu ^a   Yamashita, Yuichi ^b   Shirakusa, Takafumi ^b   Yamada, Akira ^a   Moriya, Fukuko ^a   Ayatuka, Hitoshi ^a   Mohamed, Elnisr Rashed ^a   Matsuoka, Kei ^a   Noguchi, Masanori ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Glucocorticoids; Immunotherapy; Peptide vaccine; Prostate cancer

Indexed keywords

ANTIANDROGEN; DEXAMETHASONE; DOCETAXEL; ESTRAMUSTINE PHOSPHATE; GONADORELIN; IMMUNOGLOBULIN G; PEPTIDE VACCINE; PREDNISOLONE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; CANCER VACCINE;

ADVANCED CANCER; AGED; ARTICLE; BONE PAIN; BUFFALO HUMP; CANCER GROWTH; CELL ACTIVITY; CELLULAR IMMUNITY; CENTRIPETAL OBESITY; CLINICAL ARTICLE; CUSHINGOID SYNDROME; CYTOTOXIC T LYMPHOCYTE; EDEMA; FATIGUE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNITY; MALE; MOON FACE; PRIORITY JOURNAL; PROSTATE CANCER; SKIN DISEASE; SKIN STRIA; VACCINATION; ANTIBODY PRODUCTION; DOSE RESPONSE; DRUG EFFECT; IMMUNOLOGY; MULTIMODALITY CANCER THERAPY; PROSTATE TUMOR; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

AGED; ANTIBODY FORMATION; ANTINEOPLASTIC AGENTS, HORMONAL; CANCER VACCINES; COMBINED MODALITY THERAPY; DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MALE; PREDNISOLONE; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 56049123157     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20847     Document Type: Article

References (26)

1. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA. TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1488-1490.
2. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-1520.
3. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Vanden Eynde B, Knuth A, Boon T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991;254:1643-1647.
4. Kawakami Y, Eliyahu S, Sakaguchi K, Robbins PF, Rivoltini L, Yannelli JR, Appella E, Rosenberg SA. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med 1994;180:347-352.
5. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ, Wunderich JR, Parkhust MA, Kawakami Y, Seipp CA, Einhorn JH, White DE. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998;4:321-327.
6. Noguchi M, Itoh K, Suekane S, Morinaga A, Sukehiro A, Suetsugu N, Katagiri K, Yamada A, Noda S. Immunological monitoring during combination of patient-oriented peptide vaccination and estramustine phosphate in patients with metastatic hormone refractory prostate cancer. Prostate 2004;60:32-45.
7. Noguchi M, Itoh K, Yao A, Mine T, Yamada A, Obata Y, Furuta M, Harada M. Immunological evaluation of individualized peptide vaccination with a low dose of estramustine for HLA-A24+ HRPC patients. Prostate 2005;63:1-12.
8. Noguchi M, Mine T, Yamada A, Obata Y, Yoshida K, Mizoguchi J, Harada M, Suekane S, Itoh K, Matsuoka K. Combination therapy of personalized peptide vaccination and low-dose estramustine phosphate for metastatic hormone refractory prostate cancer patients: An analysis of prognostic factors in the treatment. Oncol Res 2007;16:341-349.
9. Sartor O, Weinberger M, Moore A, Li A, Figg WD. Effect of prednisone on prostate-specific antigen in patients with hormone-refractory prostate cancer. Urology 1998;52:252-256.
10. Kelly WK, Curley T, Leibretz C, Dnistrian A, Schwartz M, Scher HI. Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer. J Clin Oncol 1995;13(9):2208-2213.
11. Kazuo Nishimura K, Nonomura N, Yasunaga Y, Takaha T, Inoue H, Sugao H, Yamaguchi S, Ukimura O, Miki T, Okuyama A. Low doses of oral dexamethasone for hormone-refractory prostate carcinoma. Cancer 2000;89:2570-2576.
12. Storlie JA, Buckner JC, Wiseman GA, Burch PA, Hartmann LC, Richardson RL. Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma. Cancer 1995;76:96-100.
13. Noguchi M, Kobayashi K, Suetugu N, Tomiyasu K, Suekane S, Yamada A, Itoh K, Noda S. Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination. Prostate 2003;57:80-92.
14. Noguchi M, Itoh K, Suekane S, Yao A, Suetsugu N, Katagiri K, Yamada A, Yamana H, Noda S. Phase I trial of patient-oriented vaccination in HLA-A2 positive patients with metastatic hormone refractory prostate cancer. Cancer Sci 2004;95:77-84.
15. + prostate cancer patients. Prostate 2003;57:152-159.
16. + prostate cancer patients. Cancer Sci 2003;94:622-627.
17. Matsueda S, Kobayashi K, Nonaka Y, Noguchi M, Itoh K, Harada M. Identification of new prostate stem cell antigen-derived peptides immunogenic in HLA-A2+ patients with hormone-refractory prostate cancer. Cancer Immunol Immun 2004;53:479-489.
18. Ogata R, Matsueda S, Yao A, Noguchi M, Itoh K. Identification of polycomb group protein enhancer of zeste homolog 2 (EZH2)-derived peptide immunogenic in HLA-A24+ prostate cancer patients. Prostate 2004;60:273-281.
19. + prostate cancer patients. Prostate 2005;62:233-242.
20. + prostate cancer patients. Br J Cancer 2004;91:287-296.
21. Mine T, Sato Y, Noguchi M, Sasatomi T, Gouhara R, Tsuda N, Tanaka S, Shomura H, Katagiri K, Rikimaru T, Shichizo S, Kamura T, Hashimoto T, Shirouzu K, Yamada A, Todo S, Itoh K, Yamana H. Humoral responses to peptides correlate with overall survival in advanced cancer patients vaccinated with peptides based on pre-existing peptide-specific cellular responses. Clin Cancer Res 2004;10:929-937.
22. Noguchi M, Kikuchi H, Ishibashi M, Noda S. Percentage of the positive area of bone metastasis is an independent predictor of the disease death in advanced prostate cancer. Br J Cancer 2003;88:195-201.
23. Yajima N, Yamanaka R, Mine T, Tsuchiya N, Homma J, Sano M, Kuramoto T, Obata Y, Komatsu N, Arima Y, Yamada A, Shigemori M, Itoh K, Tanaka R. Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma. Clin Cancer Res 2005;11(16):5900-5911.
24. White RH, Chipps BE. Reduction of serum testosterone levels during chronic glucocorticoid therapy. Ann Intern Med 1986;104:648-651.
25. Fakih M, Johnson CS, Trump D. Glucocorticoids and treatment of prostate cancer: A preclinical and clinical review. Urology 2002;60:553-561.
26. Noguchi M, Yao A, Harada M, Nakashima O, Komohara Y, Yamada S, Itoh K, Matsuoka K. Immunological evaluation of neoadjuvant peptide vaccination before radical prostatectomy for patients with localized prostate cancer. Prostate 2007;67:933-942.